G15 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 297

Clinical Trials

Multiple clinical trials evaluate interventions for conditions such as insulin resistance, coronary artery disease, acute lung injury, masticatory dysfunction, post-exercise energy intake, and peripheral vasoconstriction disorders. These studies encompass Phase I protocols investigating whole-body glucose metabolism alongside non-phased trials examining tissue perfusion, masticatory performance, and autonomic vagus nerve stimulation. Supported by academic and healthcare institutions including the National Institute on Aging and the Federal University of São Paulo, their recruitment statuses currently include completed, terminated, and unknown.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07050017	COMPLETED	Appetite; Energy Intake; Post-exercise; Negative Energy Balance	Hacettepe University	2025-05-29
NCT05173259	COMPLETED	Chewing Problem; Mastication Disorder	University of Barcelona	2021-12-01
NCT03753022	UNKNOWN	Coronary Artery Disease; Coronary Artery Bypass Grafting; Acute Lung Injury	Federal University of São Paulo	2012-01
NCT04130893	TERMINATED	Vasoconstriction Disorder of Extremities	Hôpital Européen Marseille	2019-01-17
NCT02518932	UNKNOWN	Insulin Resistance	Elahi, Dariush, PhD	2015-03	PHASE1
NCT02518932	Unknown status	Insulin Resistance	Elahi Dariush PhD\|ICON plc\|Massachusetts General Hospital\|National Institute on Aging (NIA)	2015-03	Phase 1

(data from https://clinicaltrials.gov, updated on 2025-10-06)

Check the G15 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

G15 functions as a selective, cell-permeable antagonist of G-protein coupled estrogen receptor 1 (GPER/GPR30), binding the receptor with nanomolar affinity to block non-genomic estrogenic signaling cascades and downstream intracellular calcium mobilization. By inhibiting GPER-mediated signal transduction, G15 modulates cellular responses involved in metabolic homeostasis and vascular tone, providing mechanistic relevance to clinical investigations in insulin resistance and cardiovascular disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).